1. Introduction {#sec1-ijms-19-03328}
===============

Retinal vein occlusion (RVO) is a potentially sight-threatening condition and one of the most common vascular diseases of the retina \[[@B1-ijms-19-03328]\]. RVO may be complicated by retinal ischemia that is associated with a poor prognosis and severe loss of visual function \[[@B1-ijms-19-03328],[@B2-ijms-19-03328]\]. Ischemia in the retina also promotes other sight-threatening complications of RVO, such as macular edema, neovascularization, and neovascular glaucoma \[[@B1-ijms-19-03328],[@B3-ijms-19-03328]\]. RVO complicated by ischemia may also be resistant to modern treatments, such as intravitreal anti-vascular endothelial growth factor (VEGF) agents and dexamethasone intravitreal implants \[[@B4-ijms-19-03328],[@B5-ijms-19-03328]\]. Ischemia in RVO is known to potentiate the upregulation of VEGF, VEGF receptor-2, platelet-derived growth factor and the inflammatory response that contributes to vision loss in RVO \[[@B6-ijms-19-03328],[@B7-ijms-19-03328],[@B8-ijms-19-03328]\]. The retinal proteome of RVO complicated by ischemia remains largely unstudied. Studying the retinal protein profile in RVO complicated by ischemia may help identify novel therapeutic targets and bring important insights into the pathological processes that take place in RVO. In the present study, we report on large-scale protein changes in an experimental model of RVO that develops retinal ischemia.

2. Results {#sec2-ijms-19-03328}
==========

2.1. Experimental Retinal Vein Occlusion (RVO) {#sec2dot1-ijms-19-03328}
----------------------------------------------

RVO was successfully induced in the right eye of each animal based on stagnation of venous blood and development of flame-shaped hemorrhages ([Figure 1](#ijms-19-03328-f001){ref-type="fig"}A). Control laser was given in the left eyes without inducing occlusion ([Figure 1](#ijms-19-03328-f001){ref-type="fig"}B). Angiography performed five days after RVO showed no re-canalization in RVO eyes ([Figure 2](#ijms-19-03328-f002){ref-type="fig"}A). Angiography also revealed that eyes with RVO developed ischemia upstream of the occluded veins ([Figure 2](#ijms-19-03328-f002){ref-type="fig"}A).

2.2. Quantification with Tandem Mass Tags (TMT) Based Proteomics {#sec2dot2-ijms-19-03328}
----------------------------------------------------------------

A total of 3791 proteins were successfully identified and quantified in all samples ([Supplementary File S1](#app1-ijms-19-03328){ref-type="app"}). Unfiltered mass spectrometry data is provided in [Supplementary File S2](#app1-ijms-19-03328){ref-type="app"}. A statistically significant change was observed in 147 proteins following experimental ischemic RVO. Among these proteins, 106 proteins were upregulated and 41 proteins were downregulated. The entire list of significantly changed proteins is given in [Supplementary File S3](#app1-ijms-19-03328){ref-type="app"}. The principal component analysis (PCA) plot revealed that the proteome of ischemic RVO was highly different from laser controls ([Figure 3](#ijms-19-03328-f003){ref-type="fig"}).

The bioinformatic analyses revealed that upregulated and downregulated proteins were involved in very different biological functions ([Figure 4](#ijms-19-03328-f004){ref-type="fig"}A--F).

2.3. Experimental RVO Results in Downregulation of Visual Perception and Neurotransmitter Transport {#sec2dot3-ijms-19-03328}
---------------------------------------------------------------------------------------------------

RVO resulted in a downregulation of proteins involved in visual perception ([Figure 4](#ijms-19-03328-f004){ref-type="fig"}A). RVO also lead to a downregulation of proteins involved in neurotransmitter transport, regulation of neurotransmitter levels, neurotransmitter secretion, and synaptic transport ([Figure 4](#ijms-19-03328-f004){ref-type="fig"}A). RVO was associated with decreased levels of proteins pertaining to photoreceptor outer segment, neuron part, and neuron projection ([Figure 4](#ijms-19-03328-f004){ref-type="fig"}C). Pathway analysis revealed a downregulation of GABAergic synapse and glutamateric synapse in RVO ([Figure 4](#ijms-19-03328-f004){ref-type="fig"}E). Downregulated proteins clustered into at least three groups ([Figure 5](#ijms-19-03328-f005){ref-type="fig"}). Downregulated clustering proteins were involved in visual perception and neurotransmitter transport ([Figure 5](#ijms-19-03328-f005){ref-type="fig"}).

Proteins involved in visual perception included rhodopsin, peripherin-2, arrestin C, cone cGMP-specific 3′,5′-cyclic phosphodiesterase (PDE6C), transducin alpha subunit, long-wave sensitive opsin, isoform 2 of cGMP-gated cation channel alpha-1 (CNGA1) and guanylyl cyclase-activating protein 1 (GCAP1) ([Figure 5](#ijms-19-03328-f005){ref-type="fig"}, [Table 1](#ijms-19-03328-t001){ref-type="table"}).

Immunohistochemistry revealed a general retinal thickening in RVO compared to controls ([Figure 6](#ijms-19-03328-f006){ref-type="fig"}A,B) and confirmed a downregulation of rhodopsin in RVO ([Figure 6](#ijms-19-03328-f006){ref-type="fig"}C,D). Downregulated clustering proteins involved in neurotransmitter transport included protein LIN-7 homolog A, complexins 2--4, glutamate decarboxylase 1 (GAD1), glutamate decarboxylase 2 (GAD2), glutaminase, glutamine synthetase, and aspartate aminotransferase ([Figure 5](#ijms-19-03328-f005){ref-type="fig"}, [Table 2](#ijms-19-03328-t002){ref-type="table"}).

2.4. Blood Coagulation, Focal Adhesion, and Inflammatory Response are Upregulated in RVO {#sec2dot4-ijms-19-03328}
----------------------------------------------------------------------------------------

RVO was followed by an upregulation of response to wounding, blood coagulation, wound healing, and response to stress ([Figure 4](#ijms-19-03328-f004){ref-type="fig"}B). RVO also activated cell adhesion and extracellular matrix organization ([Figure 4](#ijms-19-03328-f004){ref-type="fig"}B). Furthermore, ischemic RVO was associated with an upregulation of proteins involved in the inflammatory response, including interleukin-18 (IL-18), S100A12, and annnexin A1 (ANXA1) ([Figure 4](#ijms-19-03328-f004){ref-type="fig"}B, [Table 3](#ijms-19-03328-t003){ref-type="table"}). RVO also resulted in increased contents of proteins pertaining to extracellular space, extracellular exosome, extracellular region part, extracellular region, and extracellular matrix ([Figure 4](#ijms-19-03328-f004){ref-type="fig"}D). RVO also caused an upregulation of proteins associated with vesicles ([Figure 4](#ijms-19-03328-f004){ref-type="fig"}D). Pathway analysis revealed that ischemic RVO was associated with increased levels of proteins involved in complement and coagulation cascades, extracellular matrix-receptor interaction, and focal adhesion ([Figure 4](#ijms-19-03328-f004){ref-type="fig"}F). RVO resulted in an upregulation of clustering plasma proteins ([Supplementary File S4](#app1-ijms-19-03328){ref-type="app"}). These plasma proteins were involved in blood coagulation and included fibrinogen chains, coagulation factors, apolipoproteins, prothrombin, antithrombin-III, and serum albumin ([Supplementary File S5](#app1-ijms-19-03328){ref-type="app"}).

2.5. Inflammation in RVO-Interleukin-18 (IL-18), S100A12, and Annexin (ANXA1) {#sec2dot5-ijms-19-03328}
-----------------------------------------------------------------------------

Nineteen proteins involved in inflammatory response were increased in content in ischemic RVO ([Table 3](#ijms-19-03328-t003){ref-type="table"}). Proteins involved in inflammatory response included scavenger receptor cysteine-rich type 1 (CD163), ANXA1, IL-18, S100A12, and lysozyme c-2 ([Table 3](#ijms-19-03328-t003){ref-type="table"}). Furthermore, a number of plasma proteins were identified to be involved in the inflammatory response ([Table 3](#ijms-19-03328-t003){ref-type="table"}). As inflammation contributes to visual impairment in RVO, the inflammatory proteins, IL-18, S100A12, ANXA1 and fibronectin, ([Table 3](#ijms-19-03328-t003){ref-type="table"}) were selected for further validation.

Mass spectrometry revealed a seven-fold upregulation of IL-18 in ischemic RVO ([Table 3](#ijms-19-03328-t003){ref-type="table"}). Western blotting confirmed the upregulation of IL-18 ([Figure 7](#ijms-19-03328-f007){ref-type="fig"}A,B). Immunohistochemistry confirmed a general upregulation of IL-18 in ischemic RVO compared to laser control ([Figure 6](#ijms-19-03328-f006){ref-type="fig"}E,F).

RVO resulted in a five-fold upregulation of S100A12, which was confirmed by Western blotting ([Figure 7](#ijms-19-03328-f007){ref-type="fig"}C,D). In ischemic RVO, S100A12 was particularly abundant in retinal ganglion cells and their dendritic processes ([Figure 6](#ijms-19-03328-f006){ref-type="fig"}G).

Immunohistochemistry confirmed an upregulation of ANXA1, which was abundant in layers with increased thickness, such as the nerve fiber layer, the ganglion cell layer, the inner plexiform layer, and the outer plexiform layer ([Figure 6](#ijms-19-03328-f006){ref-type="fig"}I). Proteomic analysis revealed a strong upregulation of fibronectin. However, the upregulation of fibronectin was not confirmed by immunohistochemistry ([Supplementary File S6](#app1-ijms-19-03328){ref-type="app"}).

3. Discussion {#sec3-ijms-19-03328}
=============

3.1. Experimental Retinal Vein Occlusion (RVO) {#sec3dot1-ijms-19-03328}
----------------------------------------------

In this study, four retinal veins were occluded in the RVO eye. Therefore, the condition that was induced corresponded best to a central retinal vein occlusion (CRVO). The porcine retina has no central vein that is accessible for laser induced vein occlusion \[[@B9-ijms-19-03328]\]. Occlusion of four retinal veins was observed to be complicated by retinal ischemia. We previously conducted studies in which only one retinal vein was occluded \[[@B10-ijms-19-03328],[@B11-ijms-19-03328],[@B12-ijms-19-03328],[@B13-ijms-19-03328]\]. Occlusion of a single retinal vein in healthy pigs does not result in retinal ischemia and retinal thickening \[[@B11-ijms-19-03328],[@B14-ijms-19-03328]\]. However, the present study revealed that retinal thickening occurs when four retinal veins are occluded. Retinal thickening observed as macular edema is a frequent complication in humans with RVO \[[@B6-ijms-19-03328],[@B15-ijms-19-03328],[@B16-ijms-19-03328]\]. Thus, retinal thickening, as observed in the present study, is a complication that is likely to occur. Indeed, an RVO model with occlusion of four retinal veins may be better suited for studying retinal thickening following RVO.

Based on the histological analyses, retinal thickening mainly occurred in the nerve fiber layer, the ganglion cell layer, the inner plexiform layer, and the outer plexiform layer ([Figure 6](#ijms-19-03328-f006){ref-type="fig"}). This finding is consistent with the fact that retinal veins drain the inner two thirds of the retina \[[@B6-ijms-19-03328],[@B9-ijms-19-03328],[@B17-ijms-19-03328]\]. On the other hand, the morphology of the retinal pigment epithelium (RPE) remained largely unchanged ([Figure 6](#ijms-19-03328-f006){ref-type="fig"}). The RPE is not likely to be affected in RVO as the RPE is drained by the choroid.

3.2. Quantification by Mass Spectrometry {#sec3dot2-ijms-19-03328}
----------------------------------------

Protein studies of RVO have mainly focused on a limited number of specific proteins \[[@B10-ijms-19-03328]\]. Our study revealed a statistically significant change in more than 100 proteins following ischemic RVO. Thus, our data indicate that pathological changes in RVO are driven by alterations in multiple proteins rather than a few vasoactive proteins.

The PCA plot ([Figure 3](#ijms-19-03328-f003){ref-type="fig"}) revealed that the proteome of ischemic RVO was highly different from laser controls. Similar differences may be observed in a clinical setting. Indeed, the proteome of an eye with ischemic RVO is likely to be highly different from a healthy fellow eye. Thus, a patient may have severe loss of visual function in one eye due to ischemic RVO whilst the fellow eye may have normal visual acuity \[[@B1-ijms-19-03328],[@B2-ijms-19-03328]\].

### 3.2.1. Visual Perception {#sec3dot2dot1-ijms-19-03328}

A number of proteins involved in visual perception were downregulated following ischemic RVO ([Table 1](#ijms-19-03328-t001){ref-type="table"}). A large proportion of these proteins were photoreceptor proteins involved in phototransduction, including rhodopsin, long-wave-sensitive opsin 1, transducin alpha subunit, PDE6C, CNGA1, and GCAP1. Compromised function of these proteins is known to cause retinal degeneration \[[@B18-ijms-19-03328],[@B19-ijms-19-03328],[@B20-ijms-19-03328]\]. Thus, the downregulation of these proteins in RVO may represent an early stage of retinal degeneration.

Ischemic RVO was also associated with a decreased level of peripherin-2, an integral membrane glycoprotein located in the outer segments of cone and rod photoreceptors \[[@B21-ijms-19-03328],[@B22-ijms-19-03328],[@B23-ijms-19-03328]\]. Peripherin-2 is required for rod and cone photoreceptor outer segment formation and function \[[@B24-ijms-19-03328],[@B25-ijms-19-03328]\], and a decreased content of peripherin-2 may affect the maintenance of photoreceptor structure.

### 3.2.2. Neurotransmitter Transport {#sec3dot2dot2-ijms-19-03328}

Downregulated proteins involved in neurotransmitter transport included the glutamate decarboxylase isoforms named GAD1 and GAD2, which catalyze the production of gamma-aminobutyric acid (GABA), the main retinal inhibitory transmitter \[[@B26-ijms-19-03328],[@B27-ijms-19-03328]\]. Thus, inhibitory neurotransmission may be compromised in ischemic RVO due to the decreased levels of GAD1 and GAD2. The downregulation of GAD1 and GAD2 may be associated with ischemic processes as decreased levels of GAD1 and GAD2 have previously been observed with retinal ischemia \[[@B28-ijms-19-03328]\].

Downregulated proteins involved in neurotransmitter transport also included complexins 2--4 ([Table 2](#ijms-19-03328-t002){ref-type="table"}). Complexins are small presynaptic proteins that control synaptic vesicle fusion and prevent spontaneous neurotransmitter release \[[@B29-ijms-19-03328]\]. Decreased levels of complexins are likely to affect synaptic vesicle fusion and neurotransmitter release.

### 3.2.3. Inflammation in RVO {#sec3dot2dot3-ijms-19-03328}

A statistically significant increase was identified in 19 proteins involved in inflammatory response ([Figure 4](#ijms-19-03328-f004){ref-type="fig"}B, [Table 3](#ijms-19-03328-t003){ref-type="table"}). The increased content of inflammatory proteins in RVO is likely to be associated with the ischemia that was observed in the RVO model. Previous studies have demonstrated that increased levels of IL-6, IL-8, and monocyte chemotactic protein-1 (MCP-1) in RVO are closely associated with the severity of retinal ischemia \[[@B7-ijms-19-03328],[@B8-ijms-19-03328],[@B30-ijms-19-03328],[@B31-ijms-19-03328]\]. Studies of the inflammatory response in RVO have primarily focused on a small number of cytokines. However, results from the present study indicated that numerous inflammatory proteins changed following ischemic RVO ([Table 3](#ijms-19-03328-t003){ref-type="table"}). Inflammatory proteins that have not previously been associated with RVO included IL-18, S100A12, lysozyme C-2, and CD163.

A number of plasma proteins were also classified as proteins involved in the inflammatory response ([Table 3](#ijms-19-03328-t003){ref-type="table"}). The biological role of these plasma proteins is difficult to interpret as the blood-retinal barrier is known to be compromised in RVO \[[@B14-ijms-19-03328]\]. A compromised blood-retinal barrier results in an influx of plasma proteins \[[@B14-ijms-19-03328]\]. Thus, the increased levels of plasma proteins may primarily represent a disruption of the blood-retinal barrier.

### 3.2.4. IL-18 {#sec3dot2dot4-ijms-19-03328}

IL-18 is a cytokine that is produced by monocytes, glial cells, and dendritic cells \[[@B32-ijms-19-03328]\]. IL-18 increases in content under inflammatory conditions where it promotes upregulation of other cytokines, chemokines, and adhesion molecules \[[@B33-ijms-19-03328]\]. The increased level of IL-18 in ischemic RVO is of interest as it is not among the interleukins that are normally associated with RVO. While other cytokines, such as IL-6 and IL-8, are known to be involved in inflammatory processes in RVO \[[@B7-ijms-19-03328],[@B8-ijms-19-03328],[@B30-ijms-19-03328]\], there are very few reports of IL-18 in RVO.

Results from animal studies indicate that IL-18 is involved in inflammation caused by ischemia. Qi et al. \[[@B34-ijms-19-03328]\] demonstrated that retinal IL-18 was upregulated in retinal ischemia in an experimental rat model of ischemia-reperfusion. Myocardic IL-18 is also increased following myocardial ischemia-reperfusion injury \[[@B33-ijms-19-03328],[@B35-ijms-19-03328]\]. IL-18 neutralizing antibodies have been found to reduce the size of myocardial infarction in animal studies \[[@B33-ijms-19-03328]\].

A protective role of IL-18 has also been proposed. Shen et al. \[[@B36-ijms-19-03328]\] found that aqueous IL-18 increased in patients with retinal vein occlusion after anti-VEGF intervention and detected a positive correlation between intraocular IL-18 and improved visual acuity. IL-18 has also been found to reduce retinal neovascularization in mice with ischemic retinopathy and to counteract VEGF-induced vascular leakage \[[@B36-ijms-19-03328]\].

Using an exploratory design the present study aimed at identifying novel proteins associated with ischemic RVO. Additional studies operating with larger samples sizes than in our study will be necessary to further establish the role of IL-18 in ischemic RVO.

### 3.2.5. S100A12 and ANXA1 {#sec3dot2dot5-ijms-19-03328}

S100A12 belongs to the S100 family of calcium binding proteins. S100A12 is secreted by activated granulocytes \[[@B37-ijms-19-03328]\] and constitutes approximately 5% of the total cytosolic amount of proteins in neutrophil granulocytes \[[@B38-ijms-19-03328],[@B39-ijms-19-03328]\]. S100A12 has chemotactic activity for mast cells and monocytes \[[@B40-ijms-19-03328]\]. Serum S100A12 is a marker of inflammatory disease as well as infectious disease \[[@B39-ijms-19-03328],[@B41-ijms-19-03328],[@B42-ijms-19-03328],[@B43-ijms-19-03328]\].

Serum S100A12 is elevated in various types of uveitis \[[@B44-ijms-19-03328],[@B45-ijms-19-03328]\]. The present study indicates that S100A12 is also associated with inflammation following ischemic RVO and ischemia. In ischemic RVO, S100A12 was highly abundant in the cell bodies and dendritic processes of retinal ganglion cells. The expression of S100A12 in retinal ganglion cells has not previously been described and may represent local inflammation following ischemic RVO.

ANXA1 belongs to the annexin superfamily of Ca^2+^-dependent phospholipid-binding proteins. ANXA1 is an important regulator of the innate immune system. ANXA1 mediates resolution of inflammatory processes and anti-inflammatory actions of glucocorticoids \[[@B46-ijms-19-03328],[@B47-ijms-19-03328]\]. Based on the anti-inflammatory features of ANXA1, it may be considered that ANXA1 counteracts the inflammatory response in ischemic RVO.

4. Materials and Methods {#sec4-ijms-19-03328}
========================

4.1. Animal Preparation {#sec4dot1-ijms-19-03328}
-----------------------

The experiments were approved by the Danish Animal Experiments Inspectorate (permission number, 2016-0201-00971, 1 July 2016). Six Danish Landrace pigs (30--40 kg) were used for the experiments. A 12-h light/dark cycle was used during the entire housing. On the day prior to the experimental procedures, the animals were fed in the morning and had access to unlimited amounts of water until the experiments were performed. Animal anesthesia was performed in accordance with Danish legislation on the care and use of laboratory animals. The procedures for animal anesthesia were approved by the Danish Animal Experiments Inspectorate (permission 2016-0201-00971). The animals were anesthesized with an intramuscular injection of Zoletil mixture consisting of ketamine 6.25 mg/mL and tiletamine 6.25 mg/mL, zolazepam 6.25 mg/mL, butorphanol 1.25 mg/mL, and xylazine 6.5 mg/mL. The dose of the Zoletil mixture was 1 mL/10 kg. Local anesthesia was performed with Oxybuprocaine Hydro 0.4% eye drops (Mydriacyl: Bausch & Lomb) and Phenylephrine 10% eye drops (Metaoxidrin; Bausch & Lomb). Dilation of the pupils was performed as previously described \[[@B10-ijms-19-03328],[@B11-ijms-19-03328]\].

4.2. Experimental Vein Occlusion {#sec4dot2-ijms-19-03328}
--------------------------------

Ischemic RVO was induced in the right eye of each animal while the left eye served as a control ([Figure 1](#ijms-19-03328-f001){ref-type="fig"}). Laser induced vein occlusion was induced as previously described \[[@B10-ijms-19-03328],[@B11-ijms-19-03328]\]. Briefly, ischemic RVO was induced in the right eyes by occluding four retinal veins close to the optic nerve head with a standard argon green laser given by indirect ophthalmoscopy using a 20 diopter lens. For each occlusion, 30--40 laser applications were used. Laser applications were performed with an energy of 400 mW and an exposure time of 550 ms. Identical laser burns were made in the left control eyes without inducing occlusion by applying the laser to areas close to the optic nerve head that were devoid of any major vessels. Fluorescein angiography was conducted five days after RVO to confirm that the veins remained occluded and to confirm that retinal ischemia developed. The eyes were enucleated 15 days after RVO was induced. Enucleation was performed by surgical removal of the eyelids and adnexa. The eye ball was then removed by cutting the optic nerve without causing any damages to the optic nerve head. Immediately after enucleation, the animals were euthanized with an intravenous injection of Euthasol 400 mg/mL (Virbac Danmark A/S, Kolding, Denmark) 0.5 mL/kg.

4.3. Sample Preparation for Mass Spectrometry {#sec4dot3-ijms-19-03328}
---------------------------------------------

Paired retinal samples from five pigs were used for tandem mass tags (TMT) based MS. Thus, samples with ischemic RVO (*n* = 5) were compared with laser controls (*n* = 5). The dissection was performed as described in previous works \[[@B11-ijms-19-03328],[@B12-ijms-19-03328]\]. Briefly, eyes used for mass spectrometry were placed on ice immediately after enucleation and blood residues were removed by rinsing the eyes with cooled saline water. The eyes were kept on ice during the entire dissection, which was performed under a microscope. The anterior segment was removed and the vitreous body was gently aspired with an 18 G needle (diameter = 1.2 mm) into a 5 mL syringe. The neurosensory retina was peeled from the retinal pigment epithelium with surgical tweezers. The neurosensory retina was peeled carefully from the RPE to ensure that the RPE remained in the eye cup. Samples containing the neurosensory retina were stored at −80 °C until further use. When sample preparation for mass spectrometry was initiated, the samples were thawed and each sample was lysed with 500 µL lysis buffer consisting of 50 µL 10% SDS added to 450 µL mM triethyl ammonium bicarbonate (TEAB). The protein concentration was determined with a non-interfering assay (NI Protein Assay, Geno Technology Inc., St. Louis, MO, USA) according to the manufacturer's instructions. In short, small volumes of the protein solutions were precipitated with the universal protein precipitating agent (UPPATM) supplied with the kit. One hundred µL of the copper solution was added to the precipitated protein. BSA was used as standard. Samples were incubated for 15--20 min. at room temperature and the absorbance at 480 nm was measured immediately after.

Reduction of disulfide bonds, alkylation with iodoacetamide, and acetone precipitation were performed as described in a previous work \[[@B13-ijms-19-03328]\]. Digestion, TMT labeling, C18 spin column purification, and high pH reversed-phase peptide fractionation into 8 fractions were performed essentially as previously described \[[@B10-ijms-19-03328]\].

4.4. Mass Spectrometry {#sec4dot4-ijms-19-03328}
----------------------

The 8 fractions containing the peptides were resuspended in 0.1% formic acid (FA) prior to liquid chromatography mass spectrometry. Peptide concentrations of the fractions were measured by fluorescence using tryptophan as the standard and by anticipating that 0.0117 g of tryptophan corresponds to 1 g of protein, as it is the case for human and mouse proteins \[[@B48-ijms-19-03328]\]. One microgram of each fraction (between 1 to 4.1 µL) was loaded for each run into a Dionex UltiMate^TM^ 3000 RSLC nano system coupled to an Orbitrap Fusion mass spectrometer (Thermo Scientific, Waltham, MA, USA) equipped with an EasySpray^TM^ ion source and an Easy-IC using fluoranthene as internal calibrant. The ion transfer tube temperature was 275 °C. Liquid chromatography and mass spectrometry using the TMT synchronous precursor selection MS3 mode were performed as described in detail in a recent study \[[@B13-ijms-19-03328]\]. Briefly, peptides were separated on an Easy Spray^TM^ analytical column at 40 °C (500 mm × 75 µm PepMap RSLC, C18, 2 µm, 100 Å, Thermo Scientific, Waltham, MA, USA). The nanoflow was set to 300 µL/min. Buffers included buffer A (0.1% FA) and buffer B (80% acetonitrile, 20% water, 0.1% FA). A gradient of 240 min was applied using a gradient of buffer B from 6 to 90%. In the Orbitrap, full scans were obtained with a mass range of 380--1500 *m*/*z* at a resolution of 120,000 with an automatic gain control (AGC) of 2 × 10^5^ and maximum injection time of 50 ms. To perform MS2 acquisitions, the precursor ions were isolated with a quadrupole mass filter. MS2 acquisitions were then performed in the linear ion trap in *m*/*z* normal auto scan range mode, applying collision-induced dissociation (CID) with a collision energy of 35%, an AGC target of 1 × 10^4^, and a maximum injection time of 50 ms. A maximum of 10 precursor ions were isolated with synchronous precursor selection using and detected in MS3 in the Orbitrap in the mass range of 120--500 *m*/*z* with high energy CID using a collision energy of 65% and an AGC target of 1 × 10^5^ and a maximum injection time of 120 ms. The quantitative data obtained with TMT labelling is reporter based with isobaric tags. Data in each channel were normalized to the total peptide amount generating data from which relative fold changes of proteins can be calculated between groups.

Raw data files were processed in Proteome Discoverer 2.1. as described in our previous study \[[@B10-ijms-19-03328]\]. Databases were downloaded in Proteome Discoverer from ProteinCenter. The Sequest HT search engine was used to search against the SwissProt *Homo sapiens* databse (SwissProt TaxID = 9606 and subtaxonomies, v2016-11-30) and the SwissProt *Sus scrofa* database (SwissProt TaxID = 9823 and subtaxonomies, v2016-11-30). For protein identification, a false discovery rate (*FDR*) \< 0.01 was applied. Mass spectrometry raw data was uploaded to ProteomeXchange.

4.5. Statistics {#sec4dot5-ijms-19-03328}
---------------

The data was uploaded to Perseus version 1.6.0.7. for filtration and statistical analyses. Contaminants were removed from the dataset based on a contaminants database downloaded with the MaxQuant software, Max Planck Institute of Biochemistry, Martinsried, Germany. TMT abundances were log2 transformed. Technical replicates were averaged by mean. Proteins that were not quantified in all the 10 samples were excluded from the dataset. At least 2 unique peptides were required for successful identification. A paired *t*-test was conducted in Perseus using the FDR method by Benjamini and Hochberg \[[@B49-ijms-19-03328]\]. The S~0~ constant in Perseus was set to 2. A protein was considered statistically significantly changed if *p* \< 0.05, *FDR* \< 0.01 and fold change \>4.0 or fold change \<0.25. Prior to calculation of fold changes, the log2 transformation of TMT values was reversed. Fold changes were then calculated as the average ratio of TMT abundance right eye/TMT abundance left eye. A PCA was conducted in Perseus with an *FDR* \< 0.01 according to the method of Benjamini and Hochberg \[[@B49-ijms-19-03328]\].

4.6. Network Analysis {#sec4dot6-ijms-19-03328}
---------------------

Bioinformatic analyses were conducted using the STRING database (version 10.5) \[[@B50-ijms-19-03328]\]. Upregulated proteins and downregulated proteins were analyzed as two individual groups. The multiple proteins function was selected in STRING. The background organism was set to *Homo sapiens* and UniProt *Homo sapiens* accession numbers of the differentially changed proteins were used. The minimum required interaction score was set to 0.700, corresponding to high confidence. For cluster analysis, the Markov Cluster algorithm was used with an inflation parameter set to 4. STRING was also used to perform Gene Ontology and KEGG pathways analyses with a Fisher's exact test corrected by the *FDR* method of Benjamini and Hochberg \[[@B49-ijms-19-03328],[@B51-ijms-19-03328]\].

4.7. Western Blotting {#sec4dot7-ijms-19-03328}
---------------------

Western blotting was performed as previously described \[[@B13-ijms-19-03328]\] using a primary monoclonal mouse anti-β-actin antibody 1:5000 (clone AC-15, Sigma-Aldrich, St. Louis, MO, USA), a primary polyclonal rabbit anti-IL-18 antibody 1:500 (MBS2026569, MyBioSource, San Diego, CA, USA), and a primary polyclonal rabbit anti-S100A12 antibody 1:100 (MBS2026249, MyBioSource, San Diego, CA, USA), diluted in 2.5% (*w*/*v*) skim milk blocking buffer. Log transformed densitometric data was used to perform a paired *t*-test.

4.8. Immunohistochemistry {#sec4dot8-ijms-19-03328}
-------------------------

Eyes from one animal were used for immunohistochemistry. Dissection and fixation were performed as previously described \[[@B13-ijms-19-03328]\]. Hematoxylin and eosin staining was performed as described by Kiernan \[[@B52-ijms-19-03328]\]. Anti-bodies used for staining included a polyclonal IgG antibody directed at IL-18 (MBS2026569, MyBioSource, San Diego, CA, USA), a polyclonal IgG antibody directed at S100A12 (MBS2026249, MyBioSource, San Diego, CA, USA), a polyclonal IgG antibody directed at ANXA1 (MBS2001804, MyBioSource, San Diego, CA, USA), a poly-clonal IgG antibody directed at fibronectin (ab23751, Abcam, Cambridge, UK), and a monoclonal IgG1 antibody directed at rhodopsin (ab190307, Abcam, Cambridge, UK). The antibodies were diluted in (1:200--1:800) in PBS + 0.3% Triton X100. The sections incubated overnight at 4 °C and were processed with EnVission (DakoCytomation) DAB. Controls were incubated with rabbit IgG~2b~ or irrelevant rabbit anti-bodies.

5. Conclusions {#sec5-ijms-19-03328}
==============

Proteome changes were studied in an RVO model that best corresponded to CRVO. This RVO model was complicated by retinal ischemia. RVO resulted in a downregulation of proteins involved in visual perception, including rhodopsin, transducin alpha subunit, transducin gamma chain, and long-wave sensitive opsin. The decreased contents of these photoreceptor proteins may represent an early stage of retinal degeneration. The decreased levels of GAD1 and GAD2 may indicate that neurotransmission is compromised in ischemic RVO, while downregulation of complexins 2--4 may affect synaptic fusion and neurotransmitter release. RVO was associated with increased retinal contents of IL-18, S100A12, and ANXA1. IL-18, and S100A12 may be important driving forces of inflammatory processes caused by ischemia. Additional studies will be required to further establish the roles of IL-18 and S100A12 in RVO. The potential of IL-18 and S100A12 as therapeutic targets may be addressed in future studies once the roles of these proteins in RVO have been established.
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Annexin A1

CNGA1

Isoform 2 of cGMP-gated cation channel alpha-1
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Guanylyl cyclase-activating protein 1

GCL

Ganglion cell layer

IL-18

Interleukin-18

ILM

IPL

Inner limiting membrane

Inner plexiform layer

IS

Photoreceptor inner segment

ONL

Outer nuclear layer

OPL

Outer plexiform layer

OS

Photoreceptor outer segment

PCA

Principal component analysis

PDE6C

Cone cGMP-specific 3′,5′-cyclic phosphodiesterase
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Retinal vein occlusion
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Vascular endothelial growth factor

![Funduscopic photos taken within 20 min after experimental retinal vein occlusion (RVO) was induced. (**A**) Eye with experimental RVO. By occluding four retinal veins a condition corresponding to central retinal vein occlusion (CRVO) was induced. Laser-induced occlusion resulted in dilation of the occluded vessels upstream of the occlusion sites. Flame-shaped hemorrhages developed shortly after vein occlusions were induced. Black arrows: Laser-induced occlusions. White arrow heads: Flame-shaped hemorrhages. (**B**) Control eye. Areas of laser applications were similar to the RVO eye. By ensuring that the laser burns in the control eye did not hit any vessels, no occlusions were induced. White arrows: Laser burns given without inducing occlusion.](ijms-19-03328-g001){#ijms-19-03328-f001}

![Fluorescein angiography. Angiography conducted five days after RVO. (**A**) Eye with RVO. Angiography revealed that no re-canalization of the occlusions occurred. Retinal ischemia was seen as dark areas of retinal non-perfusion. Yellow arrows: Sites of occlusion. Blue arrow: Retinal ischemia. (**B**) Control eye. Laser burns were created without inducing RVO. No retinal ischemia was observed. White arrow: Retinal changes after laser applications.](ijms-19-03328-g002){#ijms-19-03328-f002}

![Principal component analysis (PCA). The PCA plot revealed that retinas with ischemic RVO could be separated from laser controls based on proteome changes.](ijms-19-03328-g003){#ijms-19-03328-f003}

![Gene Ontology analysis of differentially regulated proteins. Downregulated and upregulated proteins were analyzed as two individual groups. Numbers refer to the number of proteins that represented a given process, compartment, or pathway. (**A**) RVO resulted in a downregulation of proteins involved in visual perception. Downregulated biological processes also included processes related to neurotransmitter regulation and neurotransmitter transport as well as synaptic transmission. (**B**) Upregulated biological processes that were upregulated in RVO included response to wounding, wound healing, blood coagulation, and response to wounding. Nineteen upregulated proteins were involved in the inflammatory response in RVO (see also Table 3). (**C**) The analysis of cellular components indicated a downregulation of proteins pertaining to neuron part, photoreceptor outer segment, and neuron projection. (**D**) Gene ontology analysis of upregulated cellular components indicated that ischemic RVO causes extracellular changes. RVO resulted in an upregulation of extracellular space, extracellular exosome, and extracellular region. (**E**) Downregulated Kyoto Encyclopedia of Genes and Genomes KEGG pathways included GABAergic synapse, phototransduction, and glutamateric synapse. (**F**) KEGG pathways that were upregulated in ischemic RVO included complement and coagulation cascade, lysosome, and focal adhesion.](ijms-19-03328-g004){#ijms-19-03328-f004}

![Cluster analysis of downregulated proteins with interactions. Proteins that were downregulated in ischemic RVO grouped into at least three clusters. One cluster was centered around photoreceptor proteins, such as rhodopsin, transducin alpha-1, and transducin gamma chain. A second cluster consisted of glutamate decarboxylase 1 (GAD1), glutamate decarboxylase 2 (GAD2), glutaminase, glutamine synthetase, and aspartate aminotransferase. The third cluster consisted of complexins 1--4 and protein LIN-7 homolog A. Gene ontology analysis showed that proteins in the cluster of photoreceptor proteins were predominantly involved in visual perception (blue color) whilst complexins and proteins involved in glutamate metabolism were involved in neurotransmitter transport (yellow color).](ijms-19-03328-g005){#ijms-19-03328-f005}

![Histology and immunohistochemistry. Scale bar = 31 µm. Reaction color: brown. (**A**,**B**) Hematoxylin and eosin (HE) staining. In RVO complicated by ischemia, increased thickness was observed in the nerve fiber layer (NFL), the ganglion cell layer (GCL), the inner plexiform layer (IPL), and the outer plexiform layer (OPL). (**C**,**D**) In RVO, rhodopsin was downregulated in the outer nuclear layer (ONL), the photoreceptor inner segments (IS), and outer segments (OS). (**E**,**F**) Immunohistochemistry confirmed a general upregulation of IL-18 in ischemic RVO. (**G**,**H**) S100A12 was abundant in retinal ganglion cells in RVO. (**I**,**J**) ANXA1 was abundant in the inner retinal layers in RVO.](ijms-19-03328-g006){#ijms-19-03328-f006}

![Western blot analysis of IL-18 and S100A12. (**A**) Protein content of IL-18 (approximately 22 kDa). (**B**) Densitometric data presented as the change of relative IL-18 expression between ischemic RVO and control samples, normalized to relative β-actin expression. Western blot analysis supported the data from mass spectrometry, though not statistically significant (*p* = 0.078). (**C**) Protein content of S100A12. (**D**) Densitometric data confirmed an upregulation of S100A12 in ischemic RVO (*p* = 0.016).](ijms-19-03328-g007){#ijms-19-03328-f007}

ijms-19-03328-t001_Table 1

###### 

Proteins involved in visual perception that were downregulated in experimental retinal vein occlusion (RVO).

  UniProt Accession   Gene Name   RVO/Control   *p*-Value       Protein Name
  ------------------- ----------- ------------- --------------- ---------------------------------------------------
  O18766              RHO         0.15          0.000278        Rhodopsin
  Q7YS78              ARR3        0.15          1.80 × 10^−7^   Arrestin-C
  P29973-2            CNGA1       0.15          0.000027        Isoform 2 of cGMP-gated cation channel alpha-1
  P43080              GUCA1A      0.17          0.000056        Guanylyl cyclase-activating protein 1
  P51160              PDE6C       0.19          7.73 × 10^−7^   Cone cGMP-specific 3′,5′-cyclic phosphodiesterase
  P23942              PRPH2       0.2           0.0003223       Peripherin-2
  P04000              OPN1LW      0.2           0.000014        Long-wave-sensitive opsin 1
  P11488              GNAT1       0.23          0.000019        Transducin alpha-1 chain

ijms-19-03328-t002_Table 2

###### 

Proteins involved in neurotransmitter transport that were downregulated in RVO.

  UniProt Accession   Gene Name   RVO/Control   *p*-Value   Protein Name
  ------------------- ----------- ------------- ----------- ----------------------------
  Q6PUV4              CPLX2       0.13          0.000077    Complexin-2
  P46410              GLUL        0.13          0.0000056   Glutamine synthetase
  P48321              GAD2        0.17          0.000014    Glutamate decarboxylase 2
  Q9Y2J               RPH3A       0.18          0.000013    Rabphilin-3A
  O14910              LIN7A       0.2           0.00014     Protein lin-7 homolog A
  Q8WVH0              CPLX3       0.22          0.00020     Complexin-3
  Q3I5G7              SNCA        0.22          0.00032     Alpha-synuclein
  P48319              GAD1        0.22          0.000026    Glutamate decarboxylase 1
  Q7Z7G2              CPLX4       0.23          0.000042    Complexin-4
  O94925              GLS         0.23          0.000023    Glutaminase kidney isoform
  Q96E17              RAB3C       0.24          0.000039    Ras-related protein Rab-3

ijms-19-03328-t003_Table 3

###### 

Proteins involved in inflammatory response that were upregulated in RVO.

  UniProt Accession   Gene Name   RVO/Control   *p*-Value   Protein Name
  ------------------- ----------- ------------- ----------- ------------------------------------------------------
  P14287              SPP1        15.59         0.000069    Osteopontin
  P29700              AHSG        11.95         0.00044     Alpha-2-HS-glycoprotein
  P30034              PF4         11.57         0.0015      Platelet factor 4
  P02671-1            FGA         11.49         0.00031     Fibrinogen alpha chain
  P07996              THBS1       11.38         0.00087     Thrombospondin-1
  P02751              FN1         10.9          0.000099    Fibronectin
  P0C0L4-1            C4A         10.78         0.00064     Complement C4-A
  Q2VL90              CD163       9.64          0.000056    Scavenger receptor cysteine-rich type 1 protein M130
  P79263              ITIH4       8.9           0.0014      Inter-alpha-trypsin inhibitor heavy chain H4
  P19619              ANXA1       8.16          0.000074    Annexin A1
  P50447              SERPINA1    7.89          0.0011      Alpha-1-antitrypsin
  Q8SPS7              HP          7.88          0.0023      Haptoglobin
  Q19AZ8              F2          7.79          0.00069     Prothrombin
  O19073              IL18        6.91          0.000022    Interleukin-18
  P01025              C3          6.79          0.00076     Complement C3
  P32394              HMOX1       6.69          0.000025    Heme oxygenase 1
  P12068              LYZ         5.36          0.00055     Lysozyme c-2
  P80310              S100A12     5.12          0.00018     S100-A12
  P38571              LIPA        4.46          0.00024     Lysosomal acid lipase/cholesteryl ester hydrolase
